PHOSPHODIESTERASE-5 INHIBITOR USE AND PROGRESSION TO HEART FAILURE IN MEN WITH CORONARY ARTERY DISEASE AND ERECTILE DYSFUNCTION

被引：0
|
作者：
Ha, A. [1 ]
Wayne, G. [2 ]
Jacobs, M. [3 ]
Kalogeropoulos, A. [3 ]
Alukal, J. [2 ]
机构：
[1] Columbia Univ Irving Med Ctr, New York, NY USA
[2] Columbia Univ Irving Med Ctr, Dept Urol, New York, NY USA
[3] Stony Brook Univ Hosp, Div Cardiol, Stony Brook, NY USA
来源：
JOURNAL OF SEXUAL MEDICINE | 2023年 / 20卷
关键词：
D O I：
暂无
中图分类号：
R5 [内科学]; R69 [泌尿科学（泌尿生殖系疾病）];
学科分类号：
1002 ; 100201 ;
摘要：
203
引用
收藏
页数：2
相关论文
共 50 条
  • [41] Vardenafil -: Treatment of erectile dysfunction -: Phosphodiesterase 5 inhibitor
    Sorbera, LA
    Martin, L
    Rabasseda, X
    Castañer, J
    DRUGS OF THE FUTURE, 2001, 26 (02) : 141 - 144
  • [42] Prevalence of asymptomatic coronary artery disease in hypertensive men with erectile dysfunction
    Terentes-Printzios, D.
    Vlachopoulos, C.
    Loakeimidis, N.
    Aggelis, A.
    Bratsas, A.
    Rokkas, K.
    Askitis, T.
    Stefanadis, C.
    JOURNAL OF SEXUAL MEDICINE, 2009, 6 : 434 - 434
  • [43] Increased erythrocyte aggregation in men with coronary artery disease and erectile dysfunction
    Justo, D.
    Mashav, N.
    Arbel, Y.
    Kinori, M.
    Steinvil, A.
    Swartzon, M.
    Molat, B.
    Halkin, A.
    Finkelstein, A.
    Heruti, R.
    Banai, S.
    INTERNATIONAL JOURNAL OF IMPOTENCE RESEARCH, 2009, 21 (03) : 192 - 197
  • [44] Increased erythrocyte aggregation in men with coronary artery disease and erectile dysfunction
    D Justo
    N Mashav
    Y Arbel
    M Kinori
    A Steinvil
    M Swartzon
    B Molat
    A Halkin
    A Finkelstein
    R Heruti
    S Banai
    International Journal of Impotence Research, 2009, 21 : 192 - 197
  • [45] THE PREVALENCE OF PHOSPHODIESTERASE-5 INHIBITOR USAGE IN MEN WITH RETROGRADE EJACULATION
    Zhou, C.
    Mumtaz, M.
    Kulla, A.
    Wiseman, B.
    Campbell, K.
    JOURNAL OF SEXUAL MEDICINE, 2024, 21
  • [46] Predictors of Phosphodiesterase Type 5 Inhibitor Treatment Failure in Patients Diagnosed With Erectile Dysfunction
    Albarakati, Muath
    El-Tholoth, Hossam S.
    Alzahrani, Abdulaziz
    Alghamdi, Omar S.
    Alquliti, Abdulrahman
    Alnuami, Musa
    Althobity, Abdalmagid
    Almardawi, Abdulmalik
    Bedaiwi, Khaled
    CUREUS JOURNAL OF MEDICAL SCIENCE, 2023, 15 (12)
  • [47] The Effect of Intracavernosal Avanafil, a Newer Phosphodiesterase-5 Inhibitor, on Neonatal Type 2 Diabetic Rats With Erectile Dysfunction
    Yilmaz, Didem
    Bayatli, Nur
    Un, Ozge
    Kadowitz, Philip J.
    Sikka, Suresh C.
    Gur, Serap
    UROLOGY, 2014, 83 (02) : 508.e7 - 508.e12
  • [48] The risk of coronary heart disease in men with erectile dysfunction - Editorial comment
    Cormio, L
    EUROPEAN UROLOGY, 2003, 44 (03) : 370 - 371
  • [49] Cardiovascular effects of the 3 phosphodiesterase-5 inhibitors approved for the treatment of erectile dysfunction
    Kloner, RA
    CIRCULATION, 2004, 110 (19) : 3149 - 3155
  • [50] The effect of erectile function on the use of phosphodiesterase-5 inhibitors after radical prostatectomy in Japanese and US men
    Namiki, Shunichi
    Kwan, Lorna
    Kagawa-Singer, Marjorie
    Arai, Yoichi
    Litwin, Mark S.
    UROLOGY, 2008, 71 (05) : 901 - 905
12345